Apixaban plus P2Y12 inhibitor and no aspirin safest for patients with both AFib and ACS
AUGUSTUS trial finds two-drug regimen most effective with fewest adverse effects NEW ORLEANS (March 17, 2019) -- Patients at high risk for heart attacks, strokes...